Ginkgo Bioworks Holdings Inc. (DNA)
NYSE · Healthcare
Ginkgo Bioworks Holdings Inc. EBITDA 2019–2025
Ginkgo Bioworks Holdings Inc. annual/quarterly ebitda history and growth rate from 2019 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Ginkgo Bioworks Holdings Inc. ebitda for the quarter ending March 31, 2026 was -58.6 M, a 11.45% decrease year-over-year.
- Ginkgo Bioworks Holdings Inc. ebitda for the twelve months ending March 31, 2026 was -486.6 M.
- Ginkgo Bioworks Holdings Inc. annual ebitda for 2025 was -256.3 M, a 48.41% decrease from 2024.
- Ginkgo Bioworks Holdings Inc. annual ebitda for 2024 was -496.7 M, a 37.43% decrease from 2023.
- Ginkgo Bioworks Holdings Inc. annual ebitda for 2023 was -793.9 M, a 63.35% decrease from 2022.
- Ginkgo Bioworks Holdings Inc. annual ebitda for 2022 was -2.2 B.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Ginkgo Bioworks Holdings Inc. EBITDA — FAQ
Ginkgo Bioworks Holdings Inc. (DNA) ebitda over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see DNA's ebitda history?
The chart and table above show Ginkgo Bioworks Holdings Inc.'s ebitda by year and by quarter, including the growth rate.